Use Case · Pharmaceuticals · Litigation Risk
Litigation Search and Monitoring for Pharmaceutical Companies in India (2026)
A pharmaceutical company is only as safe as its supply chain and its partners. Active ingredients come from API suppliers, products are made at contract manufacturing sites, and medicines reach patients through distributors and stockists, with research partners and licensors in the mix. Each of these is a counterparty whose own litigation, regulatory trouble or insolvency can stop a line, taint a batch, or drag the company into a dispute. This page explains why a pharma company screens the litigation history of its counterparties and keeps watching them, the sector risks that matter, where the check sits in the workflow, and how it runs across a large vendor base. It is written for a buyer evaluating this, and is not legal advice. Last verified October 2026.
- What to screen: API suppliers, contract manufacturers, distributors, research partners and licensors, and their directors and guarantors.
- What matters: regulatory and quality prosecutions, counterparty insolvency and recovery, trade and labour disputes, product liability and patent matters.
- When: at supplier and distributor onboarding, during M&A and licensing, and continuously on critical partners.
- Honesty: "nothing on record" is not a clean chit, a common-name hit needs a confidence flag, a criminal case is an allegation, and this is not a credit score.
01Why pharma companies run a litigation check
Quality audits and regulatory licences tell a pharma company whether a partner can make a product to standard. They do not tell it whether that partner is facing a winding-up petition, has a criminal complaint open against its directors, or is in a recovery fight that could cut off supply. That information lives in court and tribunal records, not in a plant audit.
For a pharma company a litigation check answers questions that quality and commercial checks miss:
- Is this supplier or manufacturer stable? An API supplier or contract site in insolvency or heavy recovery is a supply risk, not just a credit risk.
- Is this distributor or stockist clean? A distributor with a pattern of cheque bounce, fraud or regulatory matters can create exposure downstream.
- Is a target or licensor carrying hidden disputes? In an acquisition or a licensing deal, undisclosed litigation changes the price and the protections.
02The sector risks to watch
Pharma litigation exposure is spread across several heads, and the mix is specific to the sector:
| Risk | Why it matters in pharma | Where it shows up |
|---|---|---|
| Regulatory and quality | Drug regulators and state authorities can prosecute for not-of-standard-quality or spurious drugs; this touches the company and its officers | Criminal and special courts, writ petitions in High Courts |
| Counterparty stability | An API supplier or contract manufacturer in insolvency or recovery can stop supply | NCLT and NCLAT, DRT, civil courts |
| Distributor and trade disputes | Recovery, cheque bounce and supply disputes with stockists and distributors | District and commercial courts |
| Labour and industrial | Plant-heavy operations carry industrial disputes and workmen claims | Labour courts, industrial tribunals, High Courts |
| Product liability and consumer | Claims over alleged harm or defective product | Consumer commissions, civil courts |
| Patent and IP | Infringement and patent disputes, common in pharma | High Courts, commercial courts |
For the patent-litigation angle specifically, see the pharma patent litigation dataset for India.
03Who to screen across the chain
The value of the check depends on searching the right parties, not just the headline supplier name. A thorough screen covers:
- API and raw-material suppliers, and the companies behind them.
- Contract manufacturers (CDMO and CMO) and loan-licence partners.
- Distributors, C&F agents and large stockists.
- Research partners, CROs and licensors.
- The directors, promoters and guarantors behind each, as individuals, since criminal and guarantee matters attach to them.
- An acquisition target or its group in an M&A or licensing deal.
Confirm the correct legal names and director identification numbers from the Ministry of Corporate Affairs records first, so the search runs against the right identities and not a lookalike.
04Where the check sits in the workflow
A pharma company runs the check at several points:
- At supplier and manufacturer onboarding. A new API supplier or contract site is screened alongside the quality audit.
- At distributor appointment. New distributors and large stockists are checked before credit and stock are extended.
- At M&A, licensing and in-licensing. A target, licensor or partner is searched as part of legal due diligence.
- Continuously. Critical suppliers, contract sites and distributors are watched so a fresh matter surfaces early.
05The cost of missing a matter
A missed case in pharma is rarely just a bad debt. A sole-source API supplier sliding into insolvency that nobody saw can halt production. A contract site with a serious regulatory prosecution can put a product and the brand at risk. A distributor with an undisclosed fraud history can create downstream liability.
In pharma the missed matter usually shows up as a supply shock or a regulatory and reputational hit, not just an unpaid invoice. Seeing it at onboarding is where the loss is prevented.
Manual search fails two ways: coverage, when a supplier, its directors or a connected company is never searched or missed on a portal, and timing, when a one-time onboarding check never catches what is filed afterwards.
06Running it across a large vendor base
A mid-size or large pharma company deals with hundreds of suppliers, contract sites and distributors, far too many to search by hand repeatedly. The practical approach is to feed a list of names into a search that runs across courts and tribunals at once and returns a structured, scored result, with the procurement, quality, legal or deal team judging what is material.
The same engine serves due diligence, where a target and its group can be resolved across forums quickly. For the general litigation-screening use case across sectors, see litigation search and monitoring for lenders, and for managing the company's own cases, litigation management for pharma companies.
07Reading the result honestly
A litigation result is an input to a decision, not a verdict, and it must be read with care:
- "Nothing on record" is not a clean chit. It means no matter was found in the registries searched, on the date searched, under the names searched. An uncovered forum or a spelling variant can still hide a case.
- A hit on a common name is not proof. Pharma companies and their directors often share names, so every finding needs a match-confidence flag and a human check before it affects a decision.
- A criminal case is not a conviction. A pending matter is an allegation; the presumption of innocence applies until a court decides.
The search is a risk input to help your team decide, not legal advice on any supplier or deal, and it is not a credit score.
08Where Claw fits
Claw is an all-in-one legaltech platform for Indian advocates, law firms, and corporate legal teams, combining AI-based case search, an AI legal assistant (Legal GPT), case management, and compliance automation across all Indian courts and tribunals.
ClawScore (at clawscore.clawlaw.in) is Claw's litigation and criminal-risk intelligence service, and it maps onto the pharma workflow across supplier onboarding, distributor appointment and due diligence. Name an API supplier, contract manufacturer, distributor, target or licensor, and ClawScore returns every matter it finds across 9,102 courts, benches and forums in one scored Excel workbook: a Summary with a ClawScore risk band (Clean, Low, Moderate or High), a Matters sheet, a Related parties sheet covering directors, promoters and guarantors, and a Coverage sheet showing what was searched. Every finding carries a match confidence, which matters when a supplier shares a name with another company. Constant Monitoring watches a list of critical suppliers and distributors and reports New filings, Changed movement and Closed disposals on daily, weekly or monthly scans. Results return in under 5 seconds, judgment search spans 30 crore+ judgments with Supreme Court decisions from 1950 and High Court decisions from 1990, and Claw does not use your searched names or documents to train its AI models. "Nothing on record" means nothing was found in these registries on the date searched under the names searched, a criminal matter is an allegation not a conviction, and the workbook is a risk input, not legal advice and not a credit score.
To see the litigation behind a supplier, contract site or distributor, run a case search across Indian courts by party name across every forum at once.
09Sources and further reading
- eCourts (district and High Court case status): ecourts.gov.in
- National Judicial Data Grid (official pendency data): njdg.ecourts.gov.in
- Central Drugs Standard Control Organisation (CDSCO): cdsco.gov.in
- Ministry of Corporate Affairs (company and director records): mca.gov.in
- Claw: clawlaw.in
This page is general information for an Indian B2B audience, not legal advice. A litigation search supports procurement, quality and deal decisions; it does not replace counsel on any specific supplier, partner or matter, and it is not a credit score.
10Frequently asked questions
Why do pharmaceutical companies need litigation screening?
Because quality audits and licences do not reveal whether a supplier, contract site or distributor is facing insolvency, recovery, a criminal complaint or a serious regulatory prosecution, all of which can halt supply, taint a product or create downstream liability. That information lives in court and tribunal records, so it is checked separately.
What litigation risks matter most for pharma?
Regulatory and quality prosecutions touching the company and its officers, counterparty stability where an API supplier or contract manufacturer faces insolvency or recovery, trade disputes with distributors and stockists, labour and industrial matters at plants, product liability and consumer claims, and patent and IP disputes, which are common in pharma.
Who should a pharma company screen?
API and raw-material suppliers, contract manufacturers and loan-licence partners, distributors, C&F agents and large stockists, research partners, CROs and licensors, and the directors, promoters and guarantors behind each as individuals. In a deal, the target and its group are screened. Confirm correct legal names and director IDs from MCA records first.
Can a litigation hit be used to drop a supplier?
Not on its own. A hit on a common name is not proof and needs a match-confidence flag and a human check, "nothing on record" is not a clean chit, and a pending criminal matter is an allegation, not a conviction. The search is a risk input to help the procurement, quality or legal team decide; it is not legal advice and not a credit score.
How is this run across hundreds of suppliers and distributors?
By feeding a list of names into a search that runs across courts and tribunals at once and returns a structured, scored result, with constant monitoring flagging new filings on critical suppliers and distributors, so the procurement, quality and legal teams focus on material hits instead of searching portal by portal.